Martingale Asset Management L P Reduces Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Martingale Asset Management L P trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 56.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,520 shares of the biopharmaceutical company's stock after selling 19,773 shares during the period. Martingale Asset Management L P's holdings in Agios Pharmaceuticals were worth $510,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in AGIO. FMR LLC grew its holdings in shares of Agios Pharmaceuticals by 283.2% in the third quarter. FMR LLC now owns 45,393 shares of the biopharmaceutical company's stock valued at $2,017,000 after purchasing an additional 33,546 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Agios Pharmaceuticals by 15.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,946 shares of the biopharmaceutical company's stock worth $531,000 after buying an additional 1,570 shares during the period. Verition Fund Management LLC bought a new stake in shares of Agios Pharmaceuticals during the third quarter valued at approximately $315,000. State Street Corp raised its position in Agios Pharmaceuticals by 10.2% during the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company's stock valued at $103,586,000 after purchasing an additional 216,484 shares in the last quarter. Finally, XTX Topco Ltd lifted its stake in Agios Pharmaceuticals by 56.2% in the third quarter. XTX Topco Ltd now owns 8,329 shares of the biopharmaceutical company's stock worth $370,000 after acquiring an additional 2,996 shares during the period.

Agios Pharmaceuticals Trading Up 1.9 %

Shares of NASDAQ:AGIO traded up $0.52 on Friday, hitting $27.66. 590,693 shares of the company were exchanged, compared to its average volume of 711,262. The firm has a market capitalization of $1.58 billion, a P/E ratio of 2.44 and a beta of 0.83. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58. The stock's 50 day moving average price is $30.87 and its 200 day moving average price is $38.78.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. On average, equities analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total transaction of $194,172.30. Following the sale, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.93% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

AGIO has been the subject of a number of recent research reports. HC Wainwright assumed coverage on shares of Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a "buy" rating and a $58.00 price objective for the company. StockNews.com lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $56.57.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.